Talk:DMXE: Difference between revisions

'''3-Me-2'-oxo-PCE''' (also known as '''Deoxymethoxetamine''', '''DMXE''', '''3D-MXE''') is a [[psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class that produces [[ketamine|ketamine-like]] [[dissociative]] effects when [[administered]]. It is structurally related to [[MXE]], [[ketamine]], [[PCE]], and [[3-MeO-PCP]].<ref>https://pubchem.ncbi.nlm.nih.gov/compound/157010705</ref>

Limited data exists about the pharmacological properties, metabolism, and toxicity of DMXE in humans, and it has a limited history of human use. It is highly advised to use [[harm reduction practices]] if using this substance.

==History and culture==

It is rarely sold on the streets and is almost exclusively sold as a gray-area research chemical alternative to the more recognizable MXE for recreational and entheogenic purposes.

==Chemistry==

DMXE (Deoxymethoxetamine), or 2-(ethylamino)-2-(3-methylphenyl)-cyclohexanone, is classed as an arylcyclohexylamine, similar to PCP, ketamine, and MXE, which include a cyclohexane ring bound to an aromatic ring along with an amine group. It is an analog of MXE (Methoxetamine) distinguished by the replacement of the methoxy group at the 3-position with a methyl group. This modification removes an oxygen atom, hence <u>Deoxy-</u>(without oxygen)-methoxetamine, creating a more hydrophobic and less bulky molecule, which slightly alters its pharmacological effects compared to MXE.

==Pharmacology==

DMXE acts as a non-competitive [[NMDA receptor antagonist]]. NMDARs (N-methyl-D-aspartate receptors) are specific types of glutamate receptors which modulate the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open.

The substance has shown a [https://en.wikipedia.org/wiki/IC50 IC₅₀] (half-maximal inhibitory concentration), which measures the potency of DMXE and related compounds in blocking NMDARs, of 0.679mM, indicating significant potency. DMXE and related compounds bind to the phcyclidine (PCP) site of NMDARs, which was determined via in silico docking results. This binding is implicated in the antagonistic activity observed, which includes the blocking of NMDA-induced inward currents in a dose-dependent manner. DMXE shows a high affinity and potent inhibitory capacity comparable to that of other MXE analogs like MXiPr and O-desmethyl MXE, with some variations in potency explained by different interactions at the receptor site. Additionally, DMXE significantly reduces excitatory postsynaptic currents (EPSCs) evoked in the presence of NMDA.<ref>Irie, T., Yanase, Y., Demizu, Y., Usami, M., & Kikura-Hanajiri, R. (2022). Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors. Journal of Pharmacological Sciences, 150(4), 233-243. https://doi.org/10.1016/j.jphs.2022.09.005</ref>

==Toxicity and harm potential==

This is because DMXE is a research chemical with a very brief history of human usage.  

{{DangerousInteractions/Intro}}

*'''US:''' DMXE itself is not scheduled, but due to its similarities to now schedule I MXE, one can be prosecuted for under the Federal Analog Act, which states any chemical "substantially similar" to a controlled substance listed in Schedule I or II to be treated as if it were listed in Schedule I, but only if intended for human consumption.

*'''CA:''' DMXE is on Schedule 1 in Canada.

*[[Dissociatives]]

*[[Arylcyclohexylamines]]

*[[Ketamine]]

==External links==

(List along order below)

==Literature==

==References==

<references />

[[Category:Arylcyclohexylamine]]

[[Category:Dissociative]]

[[Category:Research chemical]]